Santoni et al. reported that myeloma cells treated with low doses of doxorubicin, melphalan, and bortezomib up-regulate DNAX accessory molecule-1 (DNAM-1) and NKG2D ligands resulting in enhanced NK cell susceptibility.[105] Additionally, tumors treated with 5-fluorouracil and IFN-α increasingly expressed the MHC-I and presented with higher numbers of infiltrating NK cells. The gene discussed is CD226; the disease is plasma cell myeloma.